Rubidium-82 clinical trials
How each study uses Rubidium-82 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Rubidium-82 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Rubidium-82
- 2
Studies by the year they started
3 studies that test it; most in 2011 (1)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Advanced Accelerator Applications (1) · Assistance Publique - Hôpitaux de Paris (1) · Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) (1)
Studies
Open first, then newest update. How each study uses Rubidium-82 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- 18F-mFBG Imaging for Myocardial Sympathetic InnervationRecruitingPhase 2Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)NCT06965621Written as Rubidium-82
- Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney CarcinomaNot yet recruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT07346404Written as 82-Rb injection
- Rubidium-82 PET and Tc-99m-MIBI SPET: A Head to Head ComparisonCompletedPhase 3Advanced Accelerator ApplicationsNCT01379677Written as Rubidium-82
Codes
What other systems call Rubidium-82 · ClinicalTrials.gg INT000638
- MeSH (NLM) C000615479Rubidium-82Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 9K730EL8KURUBIDIUM RB-82Confirmed FDA, NLM, Wikidata
- Wikidata Q2860122rubidium-82Confirmed FDA, NLM, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000615479 | Rubidium-82 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 9K730EL8KU | RUBIDIUM RB-82 | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q2860122 | rubidium-82 | Confirmed FDA, NLM, Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.